Navigation Links
R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
Date:9/10/2007

art 1 is to explore the effect of food on the pharmacokinetics of

R7128. Preliminary data from the single ascending dose portion of the

study indicate:

-- All doses of R7128 studied were generally safe and well-tolerated.

-- All patients completed the study, and none experienced

gastrointestinal adverse events or serious adverse events during

the study.

-- No hematological or laboratory abnormalities of clinical

significance were noted.

- Part 2 is a multiple ascending dose study of R7128 conducted in 40

patients chronically infected with HCV genotype 1 who have previously

failed interferon therapy. The primary objective of Part 2 is to

assess the safety, tolerability and pharmacokinetics of R7128 after

once-daily or twice-daily dosing for 14 days. The secondary objective

is to assess antiviral activity by measuring the change in HCV RNA.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The World Health Organization estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2009)... GRAND RAPIDS, Mich., Dec. 7 On ... ribbon on its eight-story, $178 million, 240,000 square ... economic and scientific opportunity both for VAI and ... to the more than $1 billion investment in ... Mile. When operating at capacity, the expansion will ...
(Date:12/7/2009)... ,, 60 people, males and females, ... antibodies generated by the vaccine specifically identified several ... BiondVax,s CEO Dr. Ron Babecoff: "This is ... realization of the Company,s vision of ensuring protection ... , BiondVax Pharmaceuticals Ltd. (TASE: ...
(Date:12/7/2009)... 7 Merieux Alliance, the Merieux,family ... its name to take on,the historic name ... held in Paris,Alain Merieux reviewed the important ... of major public health challenges including infectious ... with Alexandre,Merieux and the management teams, he ...
Breaking Medicine Technology:Van Andel Institute Cuts Ribbon on $178 Million Expansion 2Van Andel Institute Cuts Ribbon on $178 Million Expansion 3Van Andel Institute Cuts Ribbon on $178 Million Expansion 4Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 2Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 3Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 4Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 5Merieux Alliance Becomes Institut Merieux 2Merieux Alliance Becomes Institut Merieux 3Merieux Alliance Becomes Institut Merieux 4Congressman Schock Gets Health Care Reform Message In A Bottle From AARP 55623 1Congressman Schock Gets Health Care Reform Message In A Bottle From AARP 55623 2Waylon Lewis of elephantjournal com 3A Boycott the Whole Foods Boycott 3B 26 Yoga Journal Conference in Estes Park 55621 1Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 1Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 2Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 3Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 4
... Experience with Antimicrobials that are Biological Basis for ... Inc. (NYSE Amex: NBY ), a ... to treat and prevent a wide range of ... today announced an exclusive agreement with Professors Markus ...
... American Association for Cancer Research -PRINCETON, N.J., April ... ) today announced preclinical efficacy and safety data ... potentially important cancer targets (CXCR4, fucosyl-GM1, glypican-3, mesothelin, ... antibody-drug conjugates. Data from the studies were presented ...
Other Medicine Technology:NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds 2NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds 3NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds 4Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer 2Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer 3Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer 4
(Date:12/7/2009)... for driving up health care costs is ... prevent disease and promote health in favor ... it has arisen," reports a groundbreaking review ... The Journal of Science and Healing. Evidence ... and wellbeing by: ameliorating pain, decreasing stress ...
(Date:12/7/2009)... throughout the Clinical Workflow , ... ... currently using point-of-care resources from EBSCO Publishing ... from a new agreement which gives healthcare providers integrated ... of relevant and current information and improved quality care. ...
(Date:12/7/2009)... Paul Pomerantz, MBA, CAE, officially has begun his work as ... (DIA). , ... Horsham, PA, USA ... Pomerantz, MBA, CAE, officially has begun his work as the ... Pomerantz was previously the executive vice president of the American ...
(Date:12/7/2009)... partners with Cure to support medical research. , ... ... its part to help find a cure for spinal cord injury: ... Catheters to its list of nearly 45,000 products., , ,Cure Medical ... facilitate finding a cure for spinal cord injury, the company donates ...
(Date:12/7/2009)... using the free tax calculator. Answer simple questions about income and watch ... ... 2009 tax return by using the free tax calculator. , , , , ... more waiting or worrying about how much the return will be or how ... , , Find out right now with a few clicks of the ...
Breaking Medicine News(10 mins):Health News:The Role of Mindfulness Meditation in Health Care Reform 2Health News:The Role of Mindfulness Meditation in Health Care Reform 3Health News:EBSCO Publishing and Zynx Health Expand Partnership for Integrated Access to Evidence-Based Content 2Health News:EBSCO Publishing and Zynx Health Expand Partnership for Integrated Access to Evidence-Based Content 3Health News:New DIA Vision And Mission Coincides With Start of Paul Pomerantz Tenure As Worldwide Executive Director 2Health News:New DIA Vision And Mission Coincides With Start of Paul Pomerantz Tenure As Worldwide Executive Director 3Health News:Online Medical Supply Superstore Adds Cure Catheters to Product Mix 2Health News:2009 Free Tax Return Calculator 2
... Climate experts and state representatives from 105 countries met Friday ... the worse impacts of global warming after five days of ... ,"The discussions ended at 3:30 a.m. Friday," said Carloa ... Climate Change (IPCC). ,Once the IPCC report is ...
... According to the information furnished by Indira Gandhi National ... Act of Parliament/State legislature// or deemed to be university ... of norms and guidelines laid down by the Distance ... its meeting held on March 23, 2007 had resolved ...
... have developed a device that can enable the blind to hear ... Rs.2,000-3,000 and it reads texts through an embedded system and converts ... ,Right now it can only read text, but later it ... ,The Agra College team that took six months to develop the ...
... James E. McGreevy appears to be knocking on a different ... news// for the right reasons. He has been welcomed into ... James E. McGreevy, who was brought up as a Roman ... at St. Bartholomew's Church in New York. He is presently ...
... the home clearly raise the risk of the allergic sensitisation ... older children//, however, the influence of the environment at home ... is the conclusion reached by scientists from the GSF – ... ,The study published by Chih-Mei Chen et al. ...
... Omega-3 fatty acids help new moms fight depression, according to ... Breastfeeding Journal. ,"Depression in new mothers is ... 20 percent of postpartum women. In some high-risk populations, the ... 50 percent. Since depression has devastating effects on both mother ...
Other Medicine News:Health News:Climate Talks Reach Consensus in Bangkok 2Health News:Cats at Home Poses Allergy Risk in Young Children 2Health News:Breastfeeding and Omega-3 Fatty Acids Help New Moms Fight Depression 2
Microwell-EIA for the detection of GAD Autoantibody....
The NPT7 blood gas analyzer measures pH/blood gases and oximetry on 90 L sample volume with a two-step sampling procedure. Clinical tests compare NPT7 accuracy to that of benchtop analyzers. 30 sampl...
... Premier 3000 simplifies and enhances ... to unique features such as ... comprehensive menu options, the GEM ... Quality Management (iQM), an internal, ...
... IRMA TRUpoint sets the standard for ... chemistries right at your patient's side ... This powerful, self contained system can ... CCU to ICU, or wherever you ...
Medicine Products: